Sichuan Kelun Pharmaceutical (002422.SZ): Bevacizumab Monoclonal Antibody for the Treatment of 2L+ HER2+ Breast Cancer Approved for Market Launch
Kelon Pharmaceutical (002422.SZ) announced that its holding subsidiary Sichuan Kelon Botai Biopharmaceutical Co., Ltd...
Sichuan Kelun Pharmaceutical (002422.SZ) announced that its controlling subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd. (referred to as "Kelun Botai"), has obtained approval from the National Medical Products Administration (NMPA) for the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (also known as A166) (Shutailai) targeting human epidermal growth factor receptor 2 (HER2). This medication is approved for use in unresectable or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs.
Related Articles
Tianfeng: "Artificial intelligence +" action accelerates the landing of "AI+ applications". It is recommended to pay attention to XD INC (02400)."
Guojin Hwen Ask Non-ferrous Metals: Supply Contraction and AI Demand Resonance, Non-ferrous Sector "CommodityStock" Value Transmission in Progress.
Through the hearing of the Hong Kong Stock Exchange, Pony.ai (PONY.US) accelerates cross-border capital globalization in the United States and Hong Kong.
Tianfeng: "Artificial intelligence +" action accelerates the landing of "AI+ applications". It is recommended to pay attention to XD INC (02400)."
Guojin Hwen Ask Non-ferrous Metals: Supply Contraction and AI Demand Resonance, Non-ferrous Sector "CommodityStock" Value Transmission in Progress.
Through the hearing of the Hong Kong Stock Exchange, Pony.ai (PONY.US) accelerates cross-border capital globalization in the United States and Hong Kong.
RECOMMEND
